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PURPOSE. The American Joint Committee on Cancer (AJCC) staging system has been validated
for use as a prognostic parameter in uveal melanoma (UM). We studied whether adding
information regarding chromosome 3 and 8q status further enhances the prognostic value of
this staging system.
METHODS. We retrospectively studied a cohort of 522 patients who had been treated for UM in
two different centers between 1999 and 2015. The mean follow-up time was 47.7 months.
Cumulative incidence curves were generated and regression analyses were performed for
different combinations of AJCC staging and chromosome status. Death due to UM metastases
was the primary endpoint.
RESULTS. In AJCC stage I cases, only patients with monosomy 3 as well as chromosome 8q gain
died due to UM metastases (P < 0.001). Among patients with stage II and III tumors, those
with monosomy 3 plus gain of chromosome 8q had the worst prognosis, whereas the clinical
outcome of those with only one of these aberrations was intermediate (P < 0.001). Patients
without monosomy 3 and 8q gain showed favorable prognosis, independent of their tumor’s
AJCC stage. In cases with monosomy 3, 8q gain, or both, adding AJCC stage improved the
predictive value. Multivariable regression analyses demonstrated that AJCC staging and
chromosome 3 and 8q status contain independent information about survival status.
CONCLUSIONS. Combining information on AJCC staging and chromosome 3 and 8q status allows
a more accurate prognostication in UM. We conclude that the prognostic value of the AJCC
staging system can be improved by adding information regarding chromosome 3 and 8q
status.
Keywords: uveal melanoma, AJCC staging, chromosome 3, chromosome 8q, prognostication
Prognostication in uveal melanoma (UM) is of importance forpatient counseling and stratification of patients in clinical
trials. A variety of patient and tumor characteristics can be used
for prognostication in UM. Parameters such as tumor size,
tumor location, and extraocular growth have been identified as
prognostic factors1–4 and this has resulted in the Tumor-Node-
Metastasis (TNM) classification. The American Joint Committee
on Cancer (AJCC) Cancer Staging Manual uses the TNM
classification to describe the different stages of various types
of cancer. The first edition, in which stages were defined for
prognostication in UM, was published in 1983.5 The current
seventh edition of the AJCC staging uses tumor size, ciliary
body involvement, and extraocular growth as its parameters for
prognostication in UM.6,7 Although the AJCC staging system for
UM is an internationally recognized and validated method to
estimate patient survival, it is currently based only on the
anatomic extent of the tumor and does not take genetic data
into account.8–10
Concurrent to the development and refinement of the
classical AJCC staging system, translational research has led to
more insight into the genetics of UM. Chromosome abnormal-
ities, such as monosomy of chromosome 3,11–13 amplification
of chromosome 8q,14–17 loss of chromosome 1p,18 and gain of
chromosome 6p,19 have been identified as prognostic param-
eters. Especially monosomy 3 (M3) and polysomy of 8q are
strongly correlated with the development of metastatic disease,
whereas polysomy of chromosome 6p in the absence of
changes in chromosomes 3 and 8 is indicative of a favorable
prognosis. Besides chromosome abnormalities, gene-expression
profiling, which divides UMs into class 1 (associated with low
metastatic risk) and class 2 (associated with high metastatic
risk) tumors,20,21 can be used for prognostication. Recently, the
prognostic importance of mutations in specific genes, such as
BAP1, EIF1AX, and SF3B1, has come to light.22–25
Both types of prognostic tumor features, anatomic and
genomic, are currently used for risk stratification of UM patients
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in trials. Damato and associates26 were the first to develop a
multifactorial algorithm to generate individualized prognostic
curves for UM patients. This algorithm takes into account
patient age and sex, the TNM size category of the tumor, as
well as histological features and chromosome 3 loss.26,27 Other
authors have since also addressed the question as to whether
the combined use of the TNM/AJCC staging system and
genomic characteristics of the tumor will allow for better risk
stratification.28,29 As proposed earlier,8,26,27 integrating the
TNM/AJCC staging system with genetics may enhance prog-
nostication in UM.
This is supported by the findings of a recent study by Bagger
et al.30 in a Danish cohort of 153 patients, which indicated that
AJCC stage III and aberrations in chromosome 3 and 8 are
independent prognostic factors. However, the relatively low
number of cases limited this study, as several risk groups did
not contain sufficient cases to perform reliable statistical
analyses.
By merging the data from the Leiden University Medical
Center (LUMC), The Netherlands, on 275 enucleated UMs and
the prior as well as more recent data of the Copenhagen
University Hospital Rigshospitalet, Denmark, we were able to
investigate the effect of combining information regarding the
AJCC staging and chromosome 3 and 8q status on prognosti-
cation in a joint cohort of 522 patients. We hypothesize that
prognostication by the AJCC staging system can be enhanced
by adding information on the chromosome 3 and 8q status of
the tumor.
METHODS
Patients
Between January 8, 1999, and December 19, 2013, a total of
366 patients underwent a primary enucleation for ciliary body
and/or choroidal melanoma at the LUMC, which has been
acknowledged as top referral center for ocular melanoma by
the Dutch Federation of University Medical Centers. The 275
cases in which the chromosome 3 status was determined are
included in this study.
The Danish cohort consists of 247 patients treated from
January 1, 2009, through July 21, 2015, at the national referral
center at Copenhagen University Hospital, which is the referral
hospital for patients in East Denmark. In Denmark, there is one
national referral center at two different locations: one for East
Denmark and one for West Denmark.
Primary enucleation was performed in 89 patients, whereas
156 patients underwent brachytherapy, one patient underwent
tumor resection, and one patient refused treatment.
Genetic information on both chromosome 3 and 8q was
available in 225 Danish cases and in 245 Dutch cases. This
yielded a total number of 470 cases that were available for
survival analyses in this study (Fig. 1).
Survival data of Dutch patients was obtained from the
Integral Cancer Center West, a regional office of the Nether-
lands Comprehensive Cancer Organisation (https://iknl.nl/
over-iknl/about-iknl), which registers information about every
cancer patient. The occurrence of metastases and the survival
status of patients are checked on a yearly basis, based on
information provided by the general practitioner and/or the
hospital. In most cases, the diagnosis of metastases is based on
the clinical evaluation of the patient by the general practition-
er. Because there is no effective treatment for metastatic UM,
follow-up in The Netherlands is neither strictly regulated nor
intensive and patients are referred back to their general
practitioner. Imaging and histologic examination to confirm
the diagnosis of metastases were done in only a minority of
patients in whom the clinical diagnosis was equivocal or in
case patients participated in a clinical trial. Follow-up was last
updated in February 2016.
FIGURE 1. Number of cases with available chromosome data.
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In the Danish cohort, all patients were offered a physical
examination, liver function tests, radiography of the thorax,
and liver ultrasonography at 3, 6, 12, 18, 24, 30, 36, 48, 60, 84,
and 120 months posttreatment. Magnetic resonance imaging
(MRI) or a computed tomography (CT) scan was performed
when metastatic spread was suspected. When the MRI or CT
scan was positive, an additional positron emission tomography
(PET)-CT scan was performed. Metastases limited to the liver
were biopsied for histopathologic and immunohistochemical
examination. Otherwise, a biopsy of the most easily accessible
site was taken. The referral center was immediately informed
when a patient died. The survival status was last updated in
March 2016. No patients were lost to follow-up in either of the
cohorts.
The Regional Research Ethics Committees in both centers
waived the need for approval of this retrospective cohort
study. This study adhered to the tenets of the Declaration of
Helsinki (World Medical Association Declaration of Helsinki
1964, ethical principles for medical research involving human
subjects).
Histologic Examination
In both centers, enucleated eyes and biopsies were fixed in 4%
neutral-buffered formalin for 48 hours and embedded in
paraffin. Hematoxylin-eosin–stained sections of 4-lm thickness
were assessed by an ocular pathologist to confirm the diagnosis
and to determine histologic tumor characteristics.
American Joint Committee on Cancer Staging
The location of the tumor in the eye, the largest basal diameter
(LBD, in millimeters), thickness (in millimeters), and the
presence of extraocular extension (5 or >5 mm) were
evaluated in histological specimens for all patients in the Dutch
cohort and for enucleated cases of the Danish cohort. In
Denmark, the AJCC staging was determined clinically (diaph-
anoscopy, ultrasonography, B-scan, and MRI) and additional
histologic evaluation was done in the 89 enucleated tumors.
Transvitreal retinochoroidal biopsies were obtained in 235
patients.30
Cytogenetic Analysis
Between 1999 and 2013, a total of 291 UMs enucleated at the
LUMC were sent in for karyotyping with or without
fluorescence in situ hybridization (FISH).31 In 62 of these
cases and four other tumors, single nucleotide polymorphism
(SNP) array was performed as well.
The regulations of the International System for Human
Cytogenetic Nomenclature, 1995, were used for describing the
karyotype. Fluorescence in situ hybridization was performed
with DNA probes specific for the centromere of chromosome 3
(probe: a-sat3; Cytocell, Cambridge, UK) and for region
3p24.3-p25 (probe: RP11–322M13; Cytocell).
A tumor was designated as having M3 or gain of
chromosome 8q on the karyogram when this abnormality
was observed in at least two cells. Alternatively, for M3, the
presence of this aberration in only one cell was sufficient
provided it was accompanied by other chromosome abnor-
malities characteristic of UM. When the chromosome aberra-
tion resulting in the gain of chromosome 8q was an
isochromosome of 8q, the presence of this aberration in only
one cell was sufficient.
Two types of SNP microarray chips were used: the
Affymetrix 250K_NSP-chip, with approximately 250,000
probes across the genome, and the Affymetrix Cytoscan HD
chip, with approximately 750,000. The ‘‘Genotyping Console
(GTC)’’ was used to determine the copy numbers and the
‘‘GTC Browser’’ to visualize the data in the analysis of the
Affymetrix 250K_NSP chips (both from Affymetrix, Santa
Clara, CA, USA). Affymetrix Cytoscan HD chips were analyzed
with ‘‘Chromosome Analysis Suite (ChAS).’’ To adjust for
partial gains or deletions, different loci per chromosome were
evaluated. Approximately 200 probes per gene locus were
averaged to determine copy numbers.
In cases of disagreement among karyotyping, FISH, and SNP,
tumors were designated as having M3 or chromosome 8q gain
when either of the tests showed the abnormality.
In the Danish cohort, the chromosome status was evaluated
in 235 tumors by FISH and multiplex ligation-dependent probe
amplification (MLPA).
Fluorescence in situ hybridization was performed using
centromeric probes for chromosomes 3 (CEP3 D3Z1) and 8
(CEP8) (both probes from Abbott Molecular, Inc., Des Plaines,
IL, USA; www.abbottmolecular.com [in the public domain]).
A minimum of 100 cells from each specimen were evaluated
when possible. Cytogenetic abnormalities were reported
when at least 10% of the analyzed cells showed the
abnormality.
Multiplex ligation-dependent probe amplification analysis
(SALSA MLPA P027 Uveal melanoma; MRC-Holland, Amster-
dam, The Netherlands) was performed on tumor tissue from all
patients treated between 2012 and 2015, and retrospectively in
patients treated between 2009 and 2011, of whom tumor
tissue was available from snap-frozen biopsies.
In cases of disagreement between FISH and MLPA, a tumor
was categorized as an M3 tumor or one having chromosome 8q
gain when one of the tests showed the chromosome
abnormality.
Statistical Analysis
For data analysis, the statistical software package SPSS v. 20.0.0
(IBM SPSS Statistics for Windows; IBM Corp., Armonk, NY,
USA) was used. Characteristics of the study population were
described by percentages, means and SDs. Pearson’s v2 tests,
Student’s t-tests, and Linear-by-Linear Association tests were
performed to evaluate statistical differences between the
Danish and the Dutch cohorts. The association between AJCC
staging and chromosome 3 and 8q status was analyzed using
the Linear-by-Linear Association test.
Cumulative incidence curves were computed, which
accounted for death by other causes than UM metastases as a
competing risk. Gray’s K-sample test was performed to
evaluate statistical significance.32 The Bonferroni correction
was applied for pairwise comparisons; R version 3.1.3 (R
Development Core Team, Vienna, Austria) was used for
computing the cumulative incidence curves using package
cmprsk version 2.2.33 Cumulative incidence rates of death due
to UM metastases (with 95% confidence intervals [CIs]) for 5
years of follow-up were calculated.
Hazard ratios (HRs) of death due to UM metastases by AJCC
stage and chromosome status were estimated in Cox regression
models of the events of melanoma-related death by censoring
for end of follow-up or death due to other causes. Time since
initial treatment of UM was used as time scale and both
unadjusted and adjusted analyses were conducted. In the
adjusted analysis, we furthermore accounted for sex and age at
treatment. Effect estimates are reported as HRs with 95% CIs.
To evaluate the effect of competing risks in the regression
model, we also performed a competing risk regression analysis
using the Fine and Gray model,34 which extends the Cox
model to account for several causes of death. The Fine and
Gray model34 also was used to generate predictions of
incidence of UM-related death at 5 years of follow-up for
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subgroups of patients based on AJCC stage and chromosome
status. The Fine and Gray model34 was applied to evaluate
possible changes in interpretation due to the competing risk
situation and the Cox model was included for ease of
interpretation. All statistical tests were two-sided and based
on the likelihood ratio test. A significance level of 5% was
applied. The statistical software R (base package survival)33
was used to apply the Fine and Gray model.34
RESULTS
Population Characteristics
The combined cohort from the two oncology centers resulted
in a group of 522 patients, of whom 49% were females. The
mean age at treatment of the primary tumor was 61.9 years.
The Danish and Dutch cohorts did not differ significantly
regarding sex and age. Concerning AJCC staging, 17% of the
tumors were stage I, more than half of the tumors (59%) were
classified as stage II, whereas 23% were stage III, and 1% stage
IV. The Dutch cohort contained more tumors of higher AJCC
stages (P ¼ 0.005) (Table 1).
The chromosome 3 status was successfully determined in
227 cases of the Danish cohort, whereas the chromosome 8q
status was known in 225 tumors. Regarding the Dutch cohort,
the chromosome 3 status was known in all cases and the
chromosome 8q status in 245 tumors. The cohorts did not
differ significantly regarding the percentage of tumors harbor-
ing M3 and gain of chromosome 8q (P ¼ 0.96 and P ¼ 0.82,
respectively).
The mean follow-up time was 55.5 months (range, 1–193)
for the Dutch cohort and 39 months (range, 2–86) for the
Danish cohort, and the combined follow-up time was 47.7
months (Table 1). At last follow-up, 149 (29%) patients had
developed metastases; 3 patients already had metastases at the
time of diagnosis of the primary tumor. During the follow-up
period, 132 patients (25%) died due to UM metastases. The
metastasis rate was higher in the Dutch cohort (P < 0.001) and
a higher percentage of the Dutch patients died due to UM
metastases (P < 0.001).
Cumulative Incidence Analysis: AJCC Staging and
Chromosome 3 and 8q Status
Cumulative incidence curves were generated for the AJCC
stages and the chromosome profiles (Fig. 2). Subcategories of
the AJCC stages were not used. AJCC stage IV was not
included in the survival analyses, because the number of
patients having this stage (n¼3) was insufficient for a reliable
analysis. Patients with only M3 or only chromosome 8q gain
were combined in a single group because they did not differ
significantly in survival (Supplementary Fig. S1), and by
combining these cases we were able to create a single group
with larger patient numbers, increasing the power of the
analysis.
The cumulative incidence analysis for the AJCC staging
showed a clearly distinct risk of death due to UM metastases for
each of the different AJCC stages (P < 0.001) (Fig. 2A). The
incidence of UM death was highest in patients with AJCC stage
III tumors (P < 0.001, pairwise comparison versus AJCC stage
II with Bonferroni correction).
The various chromosome profiles were associated with a
different incidence of metastatic death (P < 0.001) (Fig. 2B).
The incidence of death from UM metastases was highest in
patients with M3 as well as chromosome 8q gain (P < 0.001,
pairwise comparison versus ‘‘M3 OR 8q gain’’ group with
Bonferroni correction), whereas patients with either M3 or
chromosome 8 gain showed an intermediate prognosis (P ¼
0.01, pairwise comparison versus ‘‘No M3 AND No 8q gain’’
group with Bonferroni correction).
TABLE 1. Characteristics of the Study Population
Characteristic Danish Cohort, n ¼ 247 Dutch Cohort, n ¼ 275 P Value Combined Cohort, n ¼ 522
Females, n (%) 132 (53) 124 (45) 0.06* 256 (49)
Mean age at primary treatment,
y (6SD)
61.9 (614.1) 61.9 (613.7) 0.99† 61.9 (613.9)
Mean tumor diameter, mm (6SD) 12.6 (64.2) 12.1 (63.5) 0.18† 12.3 (63.8)
Mean tumor thickness, mm (6SD) 5.6 (63.2) 7.0 (63.0) <0.001† 6.4 (63.2)
Extraocular growth, n (%) 8 (3) 27 (10) 0.003* 35 (7)
Ciliary body involvement, n (%) 56 (23) 113 (41) <0.001* 169 (32)
AJCC stages, n (%)
I 60 (24) 31 (11) 91 (17)
II 135 (55) 175 (64) 310 (59)
III 49 (20) 69 (25) 118 (23)
IV 3 (1) 0 (0) 0.005‡ 3 (1)
Monosomy 3, n (%) 120 (53) (known in 227 cases) 146 (53) (known in all cases) 0.96* 266 (53) (known in 502 cases)
Chromosome 8q gain, n (%) 108 (48) (known in 225 cases) 115 (47) (known in 245 cases) 0.82* 223 (47) (known in 470 cases)
Metastases, n (%) 48 (19) 101 (37) <0.001* 149 (29)
Survival, n (%)
Death due to UM metastases 43 (17) 89 (32) 132 (25)
Death due to other reasons 20 (8) 41 (15) 61 (12)
Alive at last follow-up date 184 (74) 145 (53) <0.001* 329 (63)
Mean follow-up length, mo (6SD) 39.0 (623.0) 55.5 (641.1) <0.001† 47.7 (634.8)
The characteristics of the Danish and the Dutch cohorts are depicted separately. Possible statistical differences between the two cohorts were
evaluated. Significant P values are italicized. Percentages are rounded and may not total 100. n, number of cases.
* Pearson’s v2.
† Student’s t-test.
‡ Linear-by-Linear Association.
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Cumulative Incidence Analysis: Adding
Chromosome 3 and 8q Status to AJCC Staging
Higher AJCC stages were associated with prognostically poor
chromosome profiles (P < 0.001) (Table 2). To evaluate the
effect of chromosomes 3 and 8q on survival when the cohort is
stratified by AJCC staging, we conducted separate cumulative
incidence analyses in tumors of the three AJCC stages (Fig. 3).
Of the patients with stage I tumors, only patients with
tumors having M3 as well as 8q gain died due to disseminated
disease (P < 0.001) (Fig. 3A). The 5-year cumulative incidence
of death due to UM metastases was 25% (95% CI 3%–59%)
(Table 3).
Stage II tumors showed a difference in incidence of UM-
related death among the three chromosome status groups (P <
0.001) (Fig. 3B), with the highest incidence of death due to UM
metastases occurring in patients with M3 as well as 8q gain (5-
year incidence: 50%, 95% CI 37%–62%) (P ¼ 0.002, pairwise
comparison versus ‘‘M3 OR 8q gain’’ group with Bonferroni
correction). The prognosis in cases with either a normal
chromosome status (5-year incidence: 11%, 95% CI 5%–19%) or
with M3 or chromosome 8q gain only (5-year incidence: 17%,
95% CI 9%–27%) was intermediate and comparable (P ¼ 0.54
with Bonferroni correction).
A similar pattern was observed in stage III tumors (P <
0.001) (Fig. 3C): patients with a tumor having M3 as well as
chromosome 8q gain had the most unfavorable outcome (5-
year incidence: 73%, 95% CI 58%–83%) (P < 0.001, pairwise
comparison versus ‘‘M3 OR 8q gain’’ group with Bonferroni
correction).
Additionally, the prognostic effect of adding only informa-
tion regarding the chromosome 3 status or the chromosome 3
status combined with the chromosome 8q status was analyzed
(Figs. 3D–F). The red curves in each of the three graphs depict
the incidence of UM-related death in all cases of the respective
AJCC stage. In case only information on chromosome 3 had
been available, stratification would have been possible (olive
green [M3] and blue [No M3] graphs). The additional effect of
also including information on the status of chromosome 8q is
shown by the green (M3 AND 8q gain) and purple (No M3
AND No 8q gain) graphs.
Cumulative Incidence Analysis: Adding AJCC
Staging to Chromosome 3 and 8q Status
In addition, we investigated whether adding information on
the AJCC staging would increase prognostic accuracy when
the chromosome status is known. Therefore, we performed
FIGURE 2. Uveal melanoma–related death in relation to different AJCC stages and chromosome status. Cumulative incidence curves are shown of
different AJCC stages and chromosome 3 and 8q profiles in the total cohort. (A) AJCC stage; (B) chromosome 3 and 8q status.
TABLE 2. The Distribution of Patients According to AJCC Stage and Chromosome 3 and 8q Status
AJCC Stage
Chromosome 3 and 8q Status
Total P ValueNo M3 and No 8q Gain Only 8q Gain Only M3 M3 and 8q Gain
I 42 3 17 13 75
II 111 42 44 86 283
III 16 10 17 66 109
IV 0 2 0 1 3
Total 169 57 78 166 470 <0.001
Only cases of which the chromosome 3 as well as the chromosome 8q status was known are included. The Linear-by-Linear Associate test was
applied.
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cumulative incidence analyses in the three groups with
different chromosome profiles, using the AJCC stage as the
factor of interest (Supplementary Fig. S2).
Considering only patients having a tumor without M3 and
without chromosome 8q gain, none with a stage I tumor died
due to metastases, whereas stage II and stage III tumors
showed a comparable incidence of UM deaths (P ¼ 0.13)
(Supplementary Fig. S2A) (5-year incidence: see Table 3).
Regarding tumors with either M3 or chromosome 8q gain,
the incidence of UM death in patients with a stage II or a stage
III tumor was largely comparable, whereas none of the stage I
cases died due to UM metastases (P ¼ 0.03) (Supplementary
Fig. S2B).
In tumors with M3 as well as chromosome 8q gain, the
incidence of death due to UM metastases was clearly higher in
patients with stage III tumors when compared with those with
stage I or stage II tumors (P < 0.001) (Supplementary Fig. S2C).
Regression Analyses
We performed a competing risk regression analysis based on
the Fine and Gray model34 for the parameters of sex, age at
treatment, AJCC stage, and chromosome status (Table 4). Sex
and age were not significantly associated with UM-related
death. American Joint Committee on Cancer stage III
(regression coefficient: 8.05) and the combination of M3 and
chromosome 8q gain (regression coefficient: 6.83) were the
characteristics with the largest regression coefficients (both P
< 0.001). As expected, age at treatment was associated with
the risk of death due to other causes.
Additionally, univariate and multivariable Cox regression
analyses were performed. All factors, except sex and age, were
significantly associated with melanoma-related death in the
multivariable model (Supplementary Table S1). American Joint
Committee on Cancer stage III tumors (HR 8.8, 95% CI 2.73–
28.39, P < 0.001) and tumors with M3 as well as 8q gain (HR
7.95, 95% CI 4.24 – 14.89, P < 0.001) showed the largest HRs,
which is in concordance with the results of the Fine and Gray
model.34
Multivariable Estimates of Incidence of UM-Related
Death
The Fine and Gray model34 was used to generate estimates of
incidence of death due to UM metastases at 5 years of follow-
up (Table 5). These largely correspond with the observed
estimates of cumulative incidence of UM-related death at 5
years of follow-up in our cohort (Table 3).
DISCUSSION
This international retrospective cohort study in 522 patients
with primary UM adds further evidence to our previously
published results30 and shows that combining two interna-
tionally recognized prognostication methods, AJCC stag-
ing6,9,10 and status of chromosomes 3 and 8q,11–17 enhances
the stratification between low-risk and high-risk patients.
The combination of both the anatomic extent and genetic
status has previously been shown by Damato et al.26,27 to be a
valid method for prognostication. The parameters in their
prognostic model, Liverpool Uveal Melanoma Prognosticator
Online (LUMPO), include largest tumor diameter, largest tumor
height, which correspond to the AJCC tumor size, extraocular
extension, and anterior tumor margin, which often will
correspond to ciliary body involvement. Additional parameters
in Damato’s model are tumor cell type, presence of extravas-
cular closed-loop matrices, and mitotic count.26
The current study takes advantage of the established TNM
cancer staging system, which adheres to general anatomical
staging principles only, and combines these data with
additional genetic information of the tumor cells, obtained by
karyotyping, FISH, SNP, and MLPA.
In our current study, the cumulative incidence of UM-
related death increased in higher AJCC stages, and patients
with a tumor having M3 as well as chromosome 8q gain had a
poorer prognosis than those with either one of the aberrations
or no aberrations at all. This is in accordance with findings of
an earlier study.35 Although there was an association between
higher AJCC stage and the frequency of chromosome
aberrations (Table 2), we found that combining the AJCC
staging and the chromosome status provides additional
information regarding UM-related death (Fig. 3; Supplementary
Fig. S2).
Interestingly, in patients with an AJCC stage I tumor, the
only patients dying of metastatic UM were those with the
worst genetic profile: a combination of M3 and chromosome
8q gain. This would suggest that in case of a tumor with a
limited anatomic extent, the combination of M3 and
chromosome 8q gain is required for these smaller tumors to
metastasize. Only one of these chromosome aberrations does
not seem to be sufficient to cause metastatic spread of these
tumors, at least not during the follow-up period of our study.
However, for AJCC stage II as well as stage III tumors, patients
with a normal chromosome status or with either M3 or
chromosome 8q gain did die due to UM metastases.
Apparently, tumors of higher AJCC stages already possess a
particular degree of malignancy that appears to affect survival
independently of chromosome status. Nevertheless, even in
these larger tumors, patients having M3 as well as chromo-
some 8q gain had the worst prognosis. The fact that a
combination of these chromosome aberrations results in a
worse survival than either of these aberrations separately has
been described previously35; however, to our knowledge,
there are no studies demonstrating this specifically in the
largest tumors (AJCC stage III).
We also analyzed whether AJCC staging has an additive
effect on the predictions made on the basis of the tumor’s
TABLE 3. The Observed 5-Year Cumulative Incidence Rates of Death
Due to UM Metastases According to AJCC Stage and Chromosome 3
and 8q Status
Chromosome 3 and 8q Status
AJCC Stage
No M3
and No 8q
Gain, %
M3 or 8q
Gain, %
M3 and 8q
Gain, %
I 0 0 25 (3–59)
II 11 (5–19) 17 (9–27) 50 (37–62)
III 9 (0–35) 32 (14–52) 73 (58–83)
The 95% CIs are indicated between parentheses.
FIGURE 3. Incidence of UM-related death for the chromosome profile groups, analyzed in the different AJCC stages. First column: the effect of
chromosome 3 and 8q status on the incidence of UM-related death in tumors of different AJCC stages ([A] AJCC stage I; [B] AJCC stage II; [C] AJCC
stage III). Second column: the prognostic effect of adding only the chromosome 3 status or the chromosome 3 status combined with the
chromosome 8q status to tumors of different AJCC stages ([D] AJCC stage I; [E] AJCC stage II; [F] AJCC stage III).
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chromosome status. In tumors with a normal chromosome 3
and 8q status, AJCC staging did not have a significant effect.
These tumors may have such a prognostically favorable genetic
profile that the anatomic extent has only a minor effect on
survival. In tumors with either M3 or chromosome 8q gain, the
difference in cumulative incidence of UM-related death
between stage II/stage III tumors and stage I cases was
obvious, whereas little difference was observed between stage
II and stage III tumors. In the group with M3 as well as
chromosome 8q gain, the effect of AJCC staging on the
incidence of UM-related death was even more apparent. The
incidence was clearly highest in patients with an AJCC stage III
tumor. Although metastatic death occurs in tumors of all AJCC
stages in this group of tumors, the AJCC stage III tumors are
located at the far end of the spectrum regarding prognosis.
Presumably, these larger tumors have had a longer time to
develop (lead-time bias) and may have accumulated additional
chromosome aberrations resulting in increased malignant
behavior.
A recent study by Correˆa and Augsburger28 reported that
gene-expression profiling and LBD are independent prognos-
tic factors for death due to UM metastases. To evaluate
whether combining information on LBD (cutoff 12 mm, the
median value in the study by Correˆa and Augsburger28) and
chromosome 3 and 8q status provides similar risk stratifica-
tion as combining AJCC staging and chromosome 3 and 8q
status, we performed additional analyses (Supplementary Fig.
S3). We found that combining AJCC staging and chromosome
3 and 8q status results in better risk stratification than the
combination of LBD (cutoff 12 mm) and chromosome status.
When only LBD with the cutoff of 12 mm is considered, the
smallest tumors (AJCC stage I) without M3 and without
chromosome 8q gain or with only one of these aberrations,
and which do not lead to death due to UM metastases (at least
not during our follow-up period) are not identified anymore
as a separate group. All cases with LBD 12 mm die due to
UM metastases, regardless of chromosome profile (Supple-
mentary Fig. S3A). Moreover, the additional prognostic effect
of LBD is less obvious and not statistically significant in the
group with M3 as well as 8q gain. Although there is a distinct
difference in the incidence of UM-related death in this group
between various AJCC stages, especially between stage II and
III (Supplementary Fig. S2C), this difference is less evident
when LBD with a cutoff of 12 mm is considered (Supple-
mentary Fig. S3E).
To evaluate the mutual contributions of predictors of
melanoma-related death and to take into account the effect
of competing risks, a competing risk regression analysis based
on the Fine and Gray model34 was performed. American Joint
Commission on Cancer stage III and the combination of M3
and chromosome 8q gain showed the highest regression
coefficients in this multivariable competing risk model. This
indicates that these risk factors contain independent informa-
tion about survival status. In accordance with the Fine and
Gray model,34 HRs for the risk factors AJCC staging and
chromosome 3 and 8q status remained statistically significant
in the multivariable Cox regression model.
The Fine and Gray model34 also was used to calculate the
estimated incidence of UM-related death at 5 years of follow-
up. This was largely in agreement with the observed values in
our cohort, supporting the validity of the regression coeffi-
cients of this multivariable model.
Our data show that adding chromosome status improves
prognostication by AJCC staging and that AJCC staging is of
additional prognostic value when aberrations in chromosome 3
and 8q status are observed. This has several implications for
prognostication in UM.
First, this knowledge may be used to further improve the
AJCC staging system. The AJCC staging system has been
evolving and has become more sophisticated over the years.
Although the seventh edition and the newly published eighth
edition of the AJCC staging system do not include genomic
information into their classification system, the authors of
these UM chapters mention that additional nonanatomical
parameters are important in UM, and that these data should be
collected as either biomarkers or data points. Including genetic
parameters may be especially valuable for the staging of UM,
because certain genetic aberrations such as M3 and chromo-
some 8q gain are strongly correlated with poor prognosis. The
results of our study indicate that including information on the
chromosome 3 and 8q status into the AJCC staging system
might be worthwhile.
Second, it shows that it is useful to add information on the
AJCC stage when the status of chromosome 3 and 8q is
known. Besides chromosome status, gene-expression profil-
ing has become a valuable tool for prognostication in UM.36,37
As it closely corresponds to chromosome 3 status, it is likely
TABLE 4. Competing Risk Regression Analysis Based on the Fine and Gray Model34
Characteristic
UM Death Other Death
Regression
Coefficient 95% CI P Value
Regression
Coefficient 95% CI P Value
Female sex 1.06 0.72 – 1.55 0.78 0.74 0.42 – 1.3 0.3
Age at treatment 1.01 0.99 – 1.02 0.25 1.05 1.02 – 1.08 <0.001
AJCC stage I reference category reference category
AJCC stage II 3.79 1.27 – 11.32 0.02 1.16 0.52 – 2.6 0.72
AJCC stage III 8.05 2.66 – 24.43 <0.001 0.57 0.21 – 1.53 0.26
No M3 AND No 8q gain reference category reference category
M3 OR 8q gain 2.1 1.03 – 4.27 0.04 1.36 0.68 – 2.73 0.39
M3 AND 8q gain 6.83 3.64 – 12.81 <0.001 1.47 0.72 – 2.97 0.29
TABLE 5. The Estimated 5-Year Incidence Rates of Death Due to UM
Metastases According to AJCC Stage and Chromosome 3 and 8q Status
Chromosome 3 and 8q Status
AJCC Stage
No M3
and No 8q
Gain, %
M3 or 8q
Gain, %
M3 and 8q
Gain, %
I 0 0 30 (0–54)
II 11 (4–17) 19 (9–27) 45 (32–55)
III 7 (0–20) 34 (12–51) 77 (64–85)
The Fine and Gray model34 was applied. The 95% CIs are indicated
between parentheses.
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that addition of the AJCC stage could improve the prognostic
value of gene-expression profiling as well. The idea that AJCC
staging could refine prognostication by gene-expression
analysis has already been proposed by Kivela¨ and Kujala in
2013.8
The strength of our study is that we have analyzed a large
international cohort of patients with accurate follow-up.
Medical charts and pathology reports were reviewed to check
the cause of death, in addition to the information reported by
the cancer registries.
Tumors that were irradiated comprised a major part of the
Danish cohort, whereas the Dutch cohort consisted of only
enucleated tumors. Because only small tumors are eligible for
radiation treatment, the Danish tumors were thinner and were
more often categorized in lower AJCC stages than the Dutch
tumors; however, combining these two cohorts has resulted in
a heterogeneous joint cohort. This makes the results of our
study applicable to irradiated as well as enucleated UM.
Furthermore, in both centers, the chromosome status was
determined by using two techniques, which yields results that
are more reliable. A problem with karyotyping combined with
FISH on cultured cells is that of the 291 cases that were sent for
analysis, 26 (9%) UMs were not evaluable and no reliable result
was obtained. Genetic analysis in the LUMC is now performed
using SNP arrays, but this technique was performed in only 66
cases in this cohort.
The main limitation of our study is that we included a
considerable number of recently diagnosed and treated
patients, who obviously have a short follow-up. This limited
our ability to identify patients dying due to UM metastases late
after diagnosis. This was particularly the case for the Danish
cohort, which showed a lower incidence of disease-specific
death due to lower AJCC stage tumors and shorter follow-up.
Although the Dutch cohort starts in 1999, most included
patients (189 of 275, 68%) were treated in the period between
2007 and 2013, which explains why the mean Dutch follow-up
time was not much longer than the follow-up time of the
Danish cohort. Additionally, although both centers used two
techniques to increase reliability of the results, the fact that the
two centers used different genetic tests with diverse sensitiv-
ities may have caused a variation in the detection rate of the
chromosome aberrations of interest. The fact that the
frequency of M3 and chromosome 8q gain between the two
centers is similar, despite more metastases and more advanced-
stage tumors in the Dutch cohort, may indicate that some
aberrations in chromosomes 3 and 8q could have been missed
in the Dutch tumors. However, no statistical difference in
survival was found between Danish and Dutch tumors without
M3 and neither in tumors without M3 and without 8q gain
(Supplementary Fig. S4).
In summary, the present study shows that AJCC staging and
chromosome 3 and 8q status yield additional information
regarding prognosis in UM. This provides an opportunity to
improve the prognostication of patients with UM. Future AJCC
staging systems for UM would be enhanced by the inclusion of
data concerning chromosomal copy number variations and
gene mutations.
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